Glycogen Synthase Kinase 3 beta
"Glycogen Synthase Kinase 3 beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycogen synthase kinase-3 type enzyme that functions in ENERGY METABOLISM; EMBRYONIC DEVELOPMENT; and NEUROGENESIS. It is also involved in PROTEIN BIOSYNTHESIS and regulates cell growth and proliferation as a component of the WNT SIGNALING PATHWAY and other signaling pathways. Certain polymorphisms in the GSK3B gene have been associated with PARKINSON DISEASE; ALZHEIMER DISEASE; and BIPOLAR DISORDER.
| Descriptor ID |
D000071679
|
| MeSH Number(s) |
D05.500.117.875.500 D08.811.913.696.620.682.700.429.500.500 D08.811.913.696.620.682.700.646.625.500 D12.644.360.300.500.500 D12.776.476.081.875.500 D12.776.476.300.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycogen Synthase Kinase 3 beta".
Below are MeSH descriptors whose meaning is more specific than "Glycogen Synthase Kinase 3 beta".
This graph shows the total number of publications written about "Glycogen Synthase Kinase 3 beta" by people in this website by year, and whether "Glycogen Synthase Kinase 3 beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 1 | 4 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycogen Synthase Kinase 3 beta" by people in Profiles.
-
Inhibition of the GSK3?/Nav1.6 complex suppresses early-stage Alzheimer's hyperexcitability. Alzheimers Dement. 2025 Jul; 21(7):e70507.
-
Axin-binding domain of glycogen synthase kinase 3? facilitates functional interactions with voltage-gated Na+?channel Nav1.6. J Biol Chem. 2025 02; 301(2):108162.
-
USF2 and TFEB compete in regulating lysosomal and autophagy genes. Nat Commun. 2024 09 27; 15(1):8334.
-
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3? inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 03 05; 17(826):eadh4475.
-
GSK-3? as a Potential Coordinator of Anabolic and Catabolic Pathways in Hepatitis C Virus Insulin Resistance. Intervirology. 2024; 67(1):6-18.
-
Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats. Sci Rep. 2023 03 15; 13(1):4277.
-
Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson's disease in Sprague Dawley rats. Biomed Pharmacother. 2022 Sep; 153:113330.
-
AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr). 2022 Feb; 45(1):41-56.
-
The GSK-3?-FBXL21 Axis Contributes to Circadian TCAP Degradation and Skeletal Muscle Function. Cell Rep. 2020 09 15; 32(11):108140.